Peptron Fails to Secure Definitive Deal with Lilly for 'Once-Monthly Obesity Drug'... Did Commercialization Experience Make the Difference?

Lilly's Partner Camurus Has Three Approved Long-Acting Products
Also Ahead in Once-Monthly Obesity Drug Trials... Camurus Prepares for Phase 2b, Peptron Files for Phase 1 Trial
Peptron to Invest an Additional KRW 79 Billion in Osong Plant No. 2; Faces KRW 24.1 Billion EB Repayment Burden

Peptron underwent a two-year technology evaluation for Eli Lilly's long-acting obesity treatment business but failed to secure a definitive agreement. Analysts say that to be selected by a big pharma company in the once-monthly formulation market, seen as a key competitive area for next-generation glucagon-like peptide (GLP)-1 obesity treatments, companies need not only technological capabilities but also real-world commercialization experience and clinical data.

According to industry sources on October 8, Peptron said in a letter to shareholders the previous day that its technology evaluation period for the SmartDepot platform with Lilly had ended on October 7. No follow-up commercialization agreement was signed. The company added that it plans to review the platform's commercialization potential, mass-production capabilities, marketability and intellectual property before holding further discussions on commercialization. Peptron shares were trading at KRW 92,300 on the KOSDAQ market as of 10 a.m. on October 8, down 29.33% from the previous day.

Peptron conducted the technology evaluation by applying its biodegradable polymer (PLGA) microsphere technology to Lilly's peptide drugs. SmartDepot's core technology uses ultrasonic spray drying to make uniformly sized microscopic beads and encapsulate peptides inside them. As the beads gradually break down in the body, the drug is released over a set period. The finished product is a powder that is mixed with a liquid and injected immediately before administration.

Sweden's Camurus is the company with which Lilly currently has an exclusive agreement to develop long-acting obesity treatments. In June 2025, Lilly signed a collaboration and licensing agreement worth up to $870 million (about KRW 1.1632 trillion) and secured worldwide exclusive rights to develop and commercialize long-acting incretin treatments using Camurus' technology. The agreement covers up to four drugs, including Lilly's glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 dual agonists. In June 2026, Lilly also exercised an option to add an amylin receptor agonist to the agreement.

Camurus' core technology is its lipid-based FluidCrystal. When a lipid solution is injected under the skin, it meets the body's fluids and turns into a gel with a liquid-crystal structure, which then releases the drug gradually. Because it can be injected directly in liquid form, it can be made into a prefilled syringe or an autoinjector. Peptron's SmartDepot requires powder to be mixed with liquid immediately before administration. By contrast, FluidCrystal is injected as a liquid, after which a drug depot (gel) forms inside the body, allowing immediate administration without any separate preparation.

Camurus is also ahead in commercialization and clinical development. It has three approved products based on FluidCrystal, including Buvidal, a treatment for opioid dependence. It has also completed a Phase 1b trial of CAM2056, its own once-monthly GLP-1 obesity treatment candidate, and plans to begin a Phase 2b trial in the second half of 2026.

The failure to reach a definitive agreement with Lilly has left Peptron facing both investment costs for production facilities and the burden of repaying its bonds. Peptron is building its second plant in Osong to produce long-acting GLP-1 treatments for commercial sale, with a target dosing frequency of once a month or less often. It plans to invest a total of KRW 89 billion, of which KRW 10 billion had been spent by the end of June. The KRW 24.1 billion exchangeable bond (EB) issued in August 2025 is also a burden. Bondholders can exchange the bonds for Peptron shares at KRW 326,895 per share, but the current share price is far lower, leaving them with no incentive to do so. If bondholders seek early repayment starting in August 2027, Peptron will have to repay the principal in cash.

This content was produced with the assistance of AI translation services.